Extending the Benefits of Targeting HER2 in Breast Cancer | Dana-Farber Cancer Institute

Описание к видео Extending the Benefits of Targeting HER2 in Breast Cancer | Dana-Farber Cancer Institute

Nancy Lin, MD, and Paolo Tarantino, MD, discuss the outcomes of a recent study on HER2-low metastatic breast cancer from the ASCO 2022 Annual Meeting. They explain how the antibody-drug conjugate (ADC) trastuzumab deruxtecan (Enhertu) is now being used to treat HER2-low breast cancers.

Комментарии

Информация по комментариям в разработке

Похожие видео